
Bain, Cinven to bid again for Stada as CEO resigns
Bain Capital and Cinven Partners have applied for an exemption from the one-year exclusion period to make a renewed public takeover offer for German pharmaceutical company Stada Arzneimittel.
Additionally, Stada CEO Matthias Wiedenfels has resigned today with immediate effect and will be replaced by Engelbert Coster Tjeenk Willink. Press reports suggest that Bain and Cinven plan to install a new CEO should their renewed takeover bid be successful.
German acquisition and takeover law (WpÜG) prevents bidders from launching multiple takeover bids in the same year unless they obtain permission from both the target company and the German Federal Financial Supervisory Authority (BaFin). Bain and Cinven's takeover offer failed at the end of June due to an insufficient acceptance rate from shareholders.
Reports also suggest that Bain and Cinven will make a renewed offer at the same price of €66 per share. The consortium is said to have secured commitments from hedge fund investors that did not previously tender their shares.
Bain declined to comment on the matter, while Cinven and Stada could not be reached for comment.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater